Tirzepatide vs Retatrutide
The current GLP-1 leader vs the emerging next-generation triple-agonist. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.
Tirzepatide
ApprovedAlso: Mounjaro, Zepbound
Tirzepatide is a man-made copy of two natural gut hormones. It works on two body signals at once, which is why it gets a lot of attention.
Retatrutide
ResearchAlso: LY3437943, UPB Reta (Triple Agonist)
Retatrutide is a lab-made copy of natural body chemicals that control hunger. It is a single string of 39 tiny building blocks called amino acids.
At a Glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| Research status | Approved | Phase3 |
| Highest-tier evidence | Peer-reviewed study | Peer-reviewed study |
| Research citations | 64 | 3 |
| Dosing routes | SubQ | — |
| Receptor targets | GIP receptor, GLP-1 receptor | — |
| Half-life | 5 days | — |
| Known side effects | 130 | 114 |
Research Areas
Top preclinical research areas — cited studies for each.
Tirzepatide
- Weight loss (~20.9%)
- Glycemic control
- Superior to semaglutide 1 mg
Retatrutide
- Antiobesity (Weight Loss)
- Weight loss / Obesity treatment
- Glycaemic control in Type 2 Diabetes
- Significant weight loss (14.9% reduction over 68 weeks)
- Significant reduction in liver fat content
How People Use It
Reported routines — research only, not medical advice.
Tirzepatide
- SubQ — Up to 15 mg
- SubQ — Once weekly subcutaneous injection
- SubQ — Once weekly injection under the skin
- SubQ — Injected once weekly
- SubQ — 36-week trial duration
- SubQ — Once weekly injection
- SubQ — Once-weekly subcutaneous dosing
- SubQ — 10 mg or 15 mg
Retatrutide
Not yet documented for Retatrutide — being compiled.
The Evidence
Key studies — click through to verify each on PubMed.
Tirzepatide
64 sourced studies
- Source
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
MetaAnalysis2022 88/100Rated 88/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Retatrutide
3 sourced studies
- Source
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
TRIUMPH-1: Phase 3 trial of retatrutide in adults with obesity or overweight and weight-related comorbidity
72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Decision Guide
How to Choose
Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.
Source Tirzepatide
Shop TirzepatideSource Retatrutide